Dual Biologic Therapy Induces Remission in Refractory Crohn's Disease With Vedolizumab and Ustekinumab.

Crohns Colitis 360 · 2025 · PMC11759274 · PMID 39867688

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

quite significantno p-value reported

This is quite significant as with each change of therapeutic class, the likelihood of attaining a clinical response to subsequent therapy reduces by 27% in previously TNFi-experienced patients. 14 Our data shows that combining UST and VDZ can help overcome the phenomenon of sub-optimal remission and response rates in TNFi experienced patients.

also in 5,695 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.